Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study. ROCCELLA Study
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs GLPG 1972 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms ROCCELLA
- Sponsors Galapagos NV
- 24 Sep 2018 According to a Galapagos NV media release, first patient has been dosed and received 9 million euros milestone payment from its collaboration partner Servier for this achievement.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.
- 13 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.